BRPI0515567A - combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase - Google Patents
combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimeraseInfo
- Publication number
- BRPI0515567A BRPI0515567A BRPI0515567-3A BRPI0515567A BRPI0515567A BR PI0515567 A BRPI0515567 A BR PI0515567A BR PI0515567 A BRPI0515567 A BR PI0515567A BR PI0515567 A BRPI0515567 A BR PI0515567A
- Authority
- BR
- Brazil
- Prior art keywords
- combinations
- adp
- ribose
- poly
- polymerase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMBINAçõES TERAPêUTICAS COMPREENDENDO INBIDOR DE POLI (ADP-RIBOSE) POLIMERASE". Esta invenção está relacionada de modo geral ao uso de 8-flúor-2-{ 4 - ¢ (metilamino)metil! fenil) } -1,3,4,5-tetraidro-6H-azepino ¢5,4,3-cd! indol-6-ona representado pela Fórmula (1) como um químio-sensibilizador que aumenta o nível da eficácia das drogas citotóxicas ou da radioterapia. Essa invenção proporciona combinações farmacêuticas de 8-flúor-2- { 4 - ¢ (metilamino)metil} fenil } -1,3,4,5-tetraidro-6H-azepino ¢5,4,3-cd! indol-6-ona, ou um sal farmaceuticamente aceitável do mesmo e pelo menos um agente terapêutico adicional, kits contendo tais combinações e utilização de tais combinações para tratar indivíduos que sofrem de doenças tais como câncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61245804P | 2004-09-22 | 2004-09-22 | |
US68300605P | 2005-05-19 | 2005-05-19 | |
PCT/IB2005/002900 WO2006033006A2 (en) | 2004-09-22 | 2005-09-09 | Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515567A true BRPI0515567A (pt) | 2008-07-29 |
Family
ID=35539252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515567-3A BRPI0515567A (pt) | 2004-09-22 | 2005-09-09 | combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060074073A1 (pt) |
EP (1) | EP1793830A2 (pt) |
JP (1) | JP2008513435A (pt) |
KR (2) | KR20090130156A (pt) |
AR (1) | AR051099A1 (pt) |
AU (1) | AU2005286190A1 (pt) |
BR (1) | BRPI0515567A (pt) |
CA (1) | CA2581200A1 (pt) |
IL (1) | IL181681A0 (pt) |
MX (1) | MX2007003314A (pt) |
NO (1) | NO20071512L (pt) |
NZ (1) | NZ553295A (pt) |
RU (1) | RU2361592C2 (pt) |
TW (1) | TW200626159A (pt) |
WO (1) | WO2006033006A2 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
ATE454893T1 (de) * | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
NZ587586A (en) | 2005-07-18 | 2012-04-27 | Bipar Sciences Inc | Treatment of cancer |
WO2007051119A1 (en) * | 2005-10-26 | 2007-05-03 | Mgi Gp, Inc. | Methods and compositions of parp inhibitors as potentiators in cancer therapy |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
EP2038654A4 (en) * | 2006-06-12 | 2010-08-11 | Bipar Sciences Inc | METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS |
WO2008030891A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof |
CN101522609A (zh) | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
CN101784268B (zh) * | 2006-11-20 | 2013-06-19 | 赛福伦公司 | 使用辐射敏化剂使肿瘤对辐射敏化的方法 |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
CN101918003A (zh) * | 2007-11-12 | 2010-12-15 | 彼帕科学公司 | 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌 |
CN101917982B (zh) * | 2007-11-12 | 2013-03-20 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌 |
AU2008333786A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
AU2009210654A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and bevacizumab to treat colorectal cancer |
JP2011515478A (ja) * | 2008-03-25 | 2011-05-19 | シェーリング コーポレイション | 結腸直腸がんを処置または予防するための方法 |
WO2010081778A1 (en) * | 2009-01-17 | 2010-07-22 | Universität Zürich | Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer |
RS55487B1 (sr) | 2010-02-12 | 2017-04-28 | Pfizer | Soli i polimorfi 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4,3-cd]indol-6-ona |
US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
KR101848131B1 (ko) * | 2013-03-27 | 2018-04-11 | 다이호야쿠힌고교 가부시키가이샤 | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 |
WO2015044177A1 (en) * | 2013-09-24 | 2015-04-02 | Universität Zu Köln | Compounds useful in the treatment of neoplastic diseases |
EP3082802B1 (en) * | 2013-12-03 | 2020-02-26 | Iomet Pharma Ltd. | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use |
AU2015206667B2 (en) | 2014-01-14 | 2020-05-14 | Nektar Therapeutics | Combination-based treatment method |
CN103772395B (zh) * | 2014-01-23 | 2016-05-11 | 中国药科大学 | 一类具有parp抑制活性的化合物、其制备方法及用途 |
AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
CR20200334A (es) | 2018-01-05 | 2021-03-09 | Cybrexa 1 Inc | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas |
US20210003580A1 (en) * | 2018-01-09 | 2021-01-07 | Board Of Regents Of The University Of Texas System | Methods of detection and treatment of hyper transcription diseases |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
JP2022541747A (ja) | 2019-07-10 | 2022-09-27 | サイブレクサ 3,インコーポレイテッド | 治療薬としての微小管標的化剤のペプチドコンジュゲート |
KR20220052918A (ko) | 2019-07-10 | 2022-04-28 | 싸이브렉사 2, 인크. | 치료제로서의 사이토톡신의 펩티드 접합체 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
BR112022021521A2 (pt) | 2020-04-28 | 2023-01-24 | Rhizen Pharmaceuticals Ag | Compostos inovadores úteis como inibidores de poli(adp-ribose)polimerase (parp) |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
IL307339A (en) | 2021-04-08 | 2023-11-01 | Rhizen Pharmaceuticals Ag | Poly(ADP-ribose) polymerase inhibitors |
WO2022271547A1 (en) * | 2021-06-21 | 2022-12-29 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4093448B2 (ja) * | 1999-01-11 | 2008-06-04 | アグロン・ファーマシューティカルズ・インコーポレーテッド | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤 |
US6346524B1 (en) * | 1999-03-30 | 2002-02-12 | Schering Corporation | Cancer treatment with temozolomide |
US20040091453A1 (en) * | 2000-06-02 | 2004-05-13 | Hiroshi Okamoto | Pancreatic langerhans beta cell proliferation promoter and apoptosis inhibitor, and screening of candidate compounds for the e drugs |
US6423705B1 (en) * | 2001-01-25 | 2002-07-23 | Pfizer Inc. | Combination therapy |
JP2006522088A (ja) * | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩 |
ATE454893T1 (de) * | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
-
2005
- 2005-09-09 CA CA002581200A patent/CA2581200A1/en not_active Abandoned
- 2005-09-09 KR KR1020097025441A patent/KR20090130156A/ko not_active Application Discontinuation
- 2005-09-09 KR KR1020077006504A patent/KR20070046183A/ko active Search and Examination
- 2005-09-09 AU AU2005286190A patent/AU2005286190A1/en not_active Abandoned
- 2005-09-09 MX MX2007003314A patent/MX2007003314A/es active IP Right Grant
- 2005-09-09 EP EP05801173A patent/EP1793830A2/en not_active Withdrawn
- 2005-09-09 RU RU2007110480/15A patent/RU2361592C2/ru active
- 2005-09-09 WO PCT/IB2005/002900 patent/WO2006033006A2/en active Application Filing
- 2005-09-09 NZ NZ553295A patent/NZ553295A/en unknown
- 2005-09-09 BR BRPI0515567-3A patent/BRPI0515567A/pt not_active Application Discontinuation
- 2005-09-09 JP JP2007531868A patent/JP2008513435A/ja active Pending
- 2005-09-20 US US11/231,470 patent/US20060074073A1/en not_active Abandoned
- 2005-09-20 AR ARP050103933A patent/AR051099A1/es unknown
- 2005-09-21 TW TW094132667A patent/TW200626159A/zh unknown
-
2007
- 2007-03-01 IL IL181681A patent/IL181681A0/en unknown
- 2007-03-22 NO NO20071512A patent/NO20071512L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20060074073A1 (en) | 2006-04-06 |
KR20090130156A (ko) | 2009-12-17 |
RU2007110480A (ru) | 2008-09-27 |
TW200626159A (en) | 2006-08-01 |
NO20071512L (no) | 2007-06-11 |
MX2007003314A (es) | 2007-08-06 |
IL181681A0 (en) | 2007-07-04 |
AU2005286190A1 (en) | 2006-03-30 |
AR051099A1 (es) | 2006-12-20 |
RU2361592C2 (ru) | 2009-07-20 |
NZ553295A (en) | 2010-04-30 |
EP1793830A2 (en) | 2007-06-13 |
CA2581200A1 (en) | 2006-03-30 |
WO2006033006A3 (en) | 2006-07-06 |
KR20070046183A (ko) | 2007-05-02 |
WO2006033006A2 (en) | 2006-03-30 |
JP2008513435A (ja) | 2008-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515567A (pt) | combinações terapêuticas compreendendo inibidor de poli (adp-ribose) polimerase | |
BRPI0415525A (pt) | derivados de imidazola e seu uso como agentes farmacêuticos | |
UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
BRPI0207961A8 (pt) | Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
AR052774A1 (es) | Inmunoterapia para trastornos autoinmunes | |
BRPI0415649A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
BRPI0407897A (pt) | derivados de cianopiridina úteis no tratamento de cáncer e outros distúrbios | |
NZ544472A (en) | Compounds and therapeutical use thereof | |
NO20100777L (no) | Kinazolinoner, slike forbindelser for anvendelse som medikament, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom | |
BRPI0410503B8 (pt) | composição tópica e uso da composição | |
WO2004103274A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
HK1104968A1 (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
HK1096392A1 (en) | Substituted heterocycles | |
BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
BRPI0519047A2 (pt) | mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores | |
BRPI0416260A (pt) | método para tratar, prevenir ou controlar uma doença ou distúrbio relacionada com amianto, e, composição farmacêutica | |
MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
BRPI0409359A (pt) | análogos quiméricos de somatostatina-dopamina | |
BRPI0406858A (pt) | Liberação controlada de agentes altamente solúveis | |
MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
BR0309757A (pt) | 6-alquilideno-penemas bicìclicos como inibidores de beta-lactamases | |
BR9909917A (pt) | Novos usos e combinações de cabergoline e pramipexole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |